China Biologic Products Holdings, Inc. engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People’s Republic of China.
Flawless balance sheet and fair value.
Share Price & News
How has China Biologic Products Holdings's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CBPO has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: CBPO exceeded the US Biotechs industry which returned -0.4% over the past year.
Return vs Market: CBPO exceeded the US Market which returned -11.9% over the past year.
Price Volatility Vs. Market
How volatile is China Biologic Products Holdings's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 year ago | Simply Wall StShould China Biologic Products Holdings Inc (NASDAQ:CBPO) Focus On Improving This Fundamental Metric?
1 year ago | Simply Wall StDoes China Biologic Products Holdings Inc's (NASDAQ:CBPO) PE Ratio Warrant A Sell?
1 year ago | Simply Wall StHow Did China Biologic Products Holdings Inc's (NASDAQ:CBPO) 6.94% ROE Fare Against The Industry?
Is China Biologic Products Holdings undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: CBPO ($108.7) is trading below our estimate of fair value ($176.9)
Significantly Below Fair Value: CBPO is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: CBPO is poor value based on its PE Ratio (30.6x) compared to the Biotechs industry average (15.4x).
PE vs Market: CBPO is poor value based on its PE Ratio (30.6x) compared to the US market (13x).
Price to Earnings Growth Ratio
PEG Ratio: CBPO is poor value based on its PEG Ratio (2.7x)
Price to Book Ratio
PB vs Industry: CBPO is good value based on its PB Ratio (2.5x) compared to the US Biotechs industry average (2.5x).
How is China Biologic Products Holdings forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CBPO's forecast earnings growth (11.5% per year) is above the savings rate (1.7%).
Earnings vs Market: CBPO's earnings (11.5% per year) are forecast to grow slower than the US market (12.3% per year).
High Growth Earnings: CBPO's earnings are forecast to grow, but not significantly.
Revenue vs Market: CBPO's revenue (11.4% per year) is forecast to grow faster than the US market (7.3% per year).
High Growth Revenue: CBPO's revenue (11.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CBPO's Return on Equity is forecast to be low in 3 years time (9.4%).
How has China Biologic Products Holdings performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CBPO has high quality earnings.
Growing Profit Margin: CBPO's current net profit margins (27.2%) are higher than last year (26.8%).
Past Earnings Growth Analysis
Earnings Trend: CBPO's earnings have grown by 11.1% per year over the past 5 years.
Accelerating Growth: CBPO's earnings growth over the past year (9.7%) is below its 5-year average (11.1% per year).
Earnings vs Industry: CBPO earnings growth over the past year (9.7%) underperformed the Biotechs industry 22%.
Return on Equity
High ROE: CBPO's Return on Equity (9.2%) is considered low.
How is China Biologic Products Holdings's financial position?
Financial Position Analysis
Short Term Liabilities: CBPO's short term assets ($1.3B) exceed its short term liabilities ($119.3M).
Long Term Liabilities: CBPO's short term assets ($1.3B) exceed its long term liabilities ($43.7M).
Debt to Equity History and Analysis
Debt Level: CBPO is debt free.
Reducing Debt: CBPO has no debt compared to 5 years ago when its debt to equity ratio was 36.2%.
Debt Coverage: CBPO has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: CBPO has no debt, therefore coverage of interest payments is not a concern.
Inventory Level: CBPO has a high level of physical assets or inventory.
Debt Coverage by Assets: CBPO's debt is covered by short term assets (assets are 1.4633607045292E+18x debt).
What is China Biologic Products Holdings's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CBPO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate CBPO's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CBPO's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CBPO's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CBPO's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Joseph Chow (57yo)
Mr. Joseph Chow serves as Senior Advisor at U.S.-China Green Investment Management Ltd. He served as Managing Director of Centurium Capital. Mr. Chow served as the Managing Director of Moelis & Company fro ...
|Chairman & CEO||0.83yr||no data||0.038% $1.6m|
|Independent Director||8yrs||no data||0.14% $6.0m|
|Director||6.33yrs||no data||0.073% $3.1m|
|Independent Director||11.67yrs||no data||0.040% $1.7m|
|Independent Director||1.67yrs||no data||no data|
|Director||2.17yrs||no data||0.0052% $217.5k|
Experienced Board: CBPO's board of directors are considered experienced (4.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 9.5%.
China Biologic Products Holdings, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: China Biologic Products Holdings, Inc.
- Ticker: CBPO
- Exchange: NasdaqGS
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$4.183b
- Shares outstanding: 38.48m
- Website: https://www.chinabiologic.com
Number of Employees
- China Biologic Products Holdings, Inc.
- Jialong International Tower
- 18th floor
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|CBPO N||BMV (Bolsa Mexicana de Valores)||Yes||New Common Stock||MX||MXN||Jul 2017|
|CBPO||NasdaqGS (Nasdaq Global Select)||Yes||New Common Stock||US||USD||Jul 2017|
|2CH||DB (Deutsche Boerse AG)||Yes||New Common Stock||DE||EUR||Jul 2017|
|0YWS||LSE (London Stock Exchange)||Yes||New Common Stock||GB||USD||Jul 2017|
China Biologic Products Holdings, Inc. engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People’s Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia. The company also provides human immunoglobulin and IVIG for original and secondary immunoglobulin deficiency, and immunoglobulin G secondary deficiency; human hepatitis B immunoglobulin for the prevention of measles and contagious hepatitis; human rabies immunoglobulin primarily for passive immunity from bites or claws by rabies or other infected animals; and human tetanus immunoglobulin for the prevention and therapy of tetanus. In addition, it offers placenta polypeptide for the treatment of cell immunity deficiency diseases, viral infection, and leucopenia, as well as assists in postoperative healing; factor VIII for treating coagulopathies; human fibrinogen; and human prothrombin complex concentrate for treating congenital and acquired clotting factor II, VII, IX, X deficiency, as well as excessive anticoagulant, vitamin K deficiency, etc. Further, the company is developing Human fibrinogen for the treatment for lack of fibrinogen and increase human fibrinogen concentration; and artificial dura and spinal dura mater products for use in brain and spinal surgeries. The company sells its products directly, as well as through distributors. The company was formerly known as China Biologic Products, Inc. and changed its name to China Biologic Products Holdings, Inc. in July 2017. China Biologic Products Holdings, Inc. is headquartered in Beijing, the People’s Republic of China.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/03/29 03:28|
|End of Day Share Price||2020/03/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.